Fig. 1: Baseline hematological and immunological associations of CMV infection in patients with melanoma.
a, Pretreatment lymphocyte count is elevated in CMV+ patients with MM (n = 124 CMV−, n = 105 CMV+; P = 9.1 × 10−5; lower and upper box hinges represent the 25th to 75th percentiles, the central line represents the median and the whiskers extend to the highest and lowest values no greater than 1.5 × IQR). b, CMV pretreatment NLR is reduced in CMV+ patients (P = 0.0015; samples and boxplot as in a). c, Flow cytometry-derived pretreatment T cell subset proportions according to CMV serostatus for CD4+ T cells (n = 41 CMV−, n = 33 CMV+; P = 0.0010 T naive, P = 7.3 × 10−4 TCM, P = 5.2 × 10−6 TEM, P = 6.6 × 10−9 TEMRA; boxplot as in a). d, CD8+ T cells (P = 1.8 × 10−6 T naive, P = 3.2 × 10−6 TCM, P = 0.068 TEM, P = 1.6 × 10−9 TEMRA; samples and boxplots as in c). e, Baseline pretreatment CD25+FOXP3+CD4+ T cells according to CMV serostatus (P = 7.6 × 10−4; samples and boxplots as in c). f, Differentially expressed genes (DEGs) according to CMV serostatus from pretreatment CD8+ T cells; y axis shows Benjamini–Hochberg-corrected −log10(Padj) derived from negative binomial Wald test using CMV− samples as a reference (n = 111 CMV−, n = 95 CMV+). g, Gene Ontology Biological Process (GOBP) analysis of DEGs from f, highlighting induction/suppression (orange and blue, respectively) of pathways involved in T cell activation in CMV seropositivity. All statistical tests were two-sided Wilcoxon rank sum unless otherwise stated. FC, fold-change; NS, not significant; TCM, central memory T cells.
